Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma

Table 5 Diagnostic advantages of serum sCD40L for differentiation of PDAC from non-cancer in cases where the levels of CA19-9 are inappropriate ^*

	Low-serum CA 19–9 subjects			High-serum CA 19–9 subjects
	Cut-off value	Sensitivity	Specificity	Cut-off value	Sensitivity	Specificity
sCD40L (ng/ml)	20000	80.0%	86.7%	20000	77.0%	85.0%

Sensitivity and specificity of serum sCD40L to differentiate PDAC from non-cancer in subjects with low-serum (≤40 ng/mL) or high-serum CA19-9 (>40 ng/mL) levels when serum CA19-9 does not correspond to a disease entity.
sCD40L, soluble CD40 ligand; CA19-9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen; PDAC, pancreatic ductal adenocarcinoma.
^* This means that the cases when CA19-9 are inappropriately high in normal subjects or inappropriately low in patients with PDAC in the validation dataset.

ISSN: 1479-5876